Teva to buy Barr Pharma for more than $7b #list #of #pharma #companies

Posted On Jul 22 2017 by

#barr pharma #from the September 2008 issue Teva to buy Barr Pharma for more than $7b. Teva Pharmaceutical confirmed its purchase of rival generic drugmaker Barr Pharmaceuticals for nearly $7.5 billion in a move that will boost Teva’s dominance as the world’s largest generic drugmaker. The deal continues consolidation of the generic-drug sector, driven by growth prospects as governments and other payers turn to the lower-priced medications and by the impending expiration of brand-name drug patents worth billions of dollars a year. Israel-based Teva Pharmaceutical Industries Ltd. said acquiring Montvale, N.J.-based Barr Pharmaceuticals Inc. the world’s No. 4 generic drug …


Hi-Tech Pharmaceuticals – Contract Pharmaceutical Manufacturing #pharmaceutical #market

Posted On Jul 22 2017 by

#hitech pharma # Protect and Strengthen Your Brand With Hi-Tech Hi-Tech Pharmaceuticals is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. Hi-Tech Pharmaceuticals is one of the world’s leading generics and branded pharmaceutical companies, providing products to customers throughout the world. The company maintains one of the industry’s broadest and highest quality product portfolios, which is regularly bolstered by an innovative and robust product pipeline. Hi-Tech Pharmaceuticals has attained leading positions in key international markets through its wide array of dosage forms and delivery …


Hi-Tech Pharma #biopharma #companies

Posted On Jul 22 2017 by

#hitech pharma # Hi-tech Pharmaceuticals “Hi-tech Pharmaceuticals is a privately owned pharmaceutical manufacturing company based in Hyderabad, India. Over the past 25 years, Hi-Tech pharmaceuticals has been a leader in liquid oral formulations manufacturing. Innovation, quality, and reliability are the three key strengths that we bring to our work. Contract manufacturing is an important focus area for Hi-Tech, and we are currently supporting several large and medium pharma clients with product development and manufacturing.” Strategy By virtue of its innovative business strategies and world class manufacturing facilities helps to sustain its position in this competitive market. Our product portfolio includes …


Barr Pharmaceutical #top #20 #pharma

Posted On Jul 22 2017 by

#barr pharma #Barr Pharmaceutical Barr Pharmaceuticals, Inc. is a holding company, whose principal subsidiaries, Barr Laboratories, Inc. and Duramed Pharmaceuticals, Inc. develop, manufacture and market generic and proprietary pharmaceuticals. The Company s product portfolio includes more than 100 generic and proprietary pharmaceutical products in core therapeutic categories including female healthcare (including oral contraceptive and hormone therapy products), oncology, cardiovascular, anti-infective and psychotherapeutic pharmaceuticals. The Company is listed on the New York Stock Exchange under the symbol BRL. With fiscal 2004 revenues of $1.3 billion, the Company currently manufactures and distributes more than 100 pharmaceutical products in core therapeutic categories including …


Hi-Tech Pharmaceuticals, Inc #pharmaceutical #companies #in #atlanta

Posted On Jul 22 2017 by

#hitech pharma # Hi-Tech Pharmaceuticals, Inc. 4/22/15 This letter concerns your products Fastin -XR, Fastin Rapid Release, and Lipodrene Extended Release, which are labeled and/or offered for sale as dietary supplements. Your product labeling lists the substance R-beta-methylphenethylamine as a dietary ingredient in the form of an extract of Acacia rigidula (leaves). This ingredient is also called, among other names, Beta-methylphenethylamine, MePEA, or BMPEA (hereinafter referred to as BMPEA). Under section 201(ff)(1) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(ff)(1)], a dietary ingredient is a vitamin; mineral; herb or other botanical; amino acid; dietary substance …


Future of Pharmaceutical Industry – pharma innovation gaps, patent expiry, empty drug pipelines #world-pharma.org

Posted On Jul 22 2017 by

#future of pharmaceutical industry # The pharmaceutical industry is facing huge challenges – described in video above and in powerpoint slides below. Notes on content: Over the last five years there has been serious lack of innovation in pharma companies and product pipelines have been emptying. It takes up to 15 years and $1 billion in investment to bring a single new treatment to market, after which there may be as little as a decade left before patents expire. But before that happens there may be serious threats to the pharmaceutical industry from generic manufacturers. And at any point in …


The Future of Pharma: Innovation #infinity #pharma

Posted On Jul 22 2017 by

#future of pharmaceutical industry # Understanding what is meant by “innovation” and how it is measured is a critical step as we look towards meeting unmet healthcare needs. Pharmaceutical and biotech leaders will join IDEA Pharma in launching the first in a series of panel discussion sessions, called “The Future of Pharma”. on the evening of January 11th 2016, at the time of the annual J. P. Morgan Healthcare Conference, San Francisco. IDEA Pharma CEO Mike Rea has 20 years’ experience in global pharma strategy and is acknowledged as the leading expert in early-phase Positioning and Value Proposition for the …


Teva Buys Drug Rival, Barr, for $ Billion #drug #chemistry

Posted On Jul 22 2017 by

#barr pharma # The New York Times Teva Buys Drug Rival, Barr, for $7.46 Billion July 19, 2008 Teva Pharmaceutical Industries said Friday that it would buy a rival generic drug maker, Barr Pharmaceuticals, for $7.46 billion to expand in both the United States and Europe. The deal is the latest in a wave of consolidation in the generic-drug sector that some analysts suspect will result in only a handful of major global players. Teva, the world’s largest generic drug company, plans to buy Barr for $66.50 a share in cash and stock. The price represents a 42 percent premium …


Shareholder Campaign: Barr Pharmaceuticals #list #pharmaceutical #companies

Posted On Jul 22 2017 by

#barr pharma # Shareholder Campaign: Barr Pharmaceuticals Barr Pharmaceuticals, Inc. was a holding company with two main subsidiaries, Barr Laboratories, Inc. and Duramed Pharmaceuticals, that focused on generic and proprietary drugs, respectively. Barr and Duramed developed, manufactured, and marketed more than 100 products. 2005 Resolution: Give the Animals 5 With the help of PETA supporters who held stock in Barr Pharmaceuticals, a resolution was filed in the fall of 2004 calling on the company to Give the Animals 5 replace five crude and cruel animal tests with state-of-the-art and scientifically valid non-animal methods that were already in use in other …


Agricultural biotechnology #pharma #drugs

Posted On Jul 22 2017 by

#biotech jobs # Agricultural biotechnology Biotechnology is used in many ways in agriculture. Agricultural biotechnology companies work to supply farmers with tools to increase the yield of plant and animal products, while lowering the costs of production. Agricultural biotechnology can also include production of plants such as orchids for ornamental purposes and plants that can be used for fuel production (biofuels). To accomplish these goals, biotechnologists develop products to protect animals and crops from disease and help farmers identify the best animals and seeds to use in selective breeding programs. For example, a commercial fish farm might raise fish like …